Your Search Returned 246 tagged news reports
An employee of Teva Pharmaceutical Industries watches pill bottles on a conveyor belt at the company's Jerusalem oral solid dosage plant (OSD) December 21, 2011...Supreme Court on Monday to stop a lower court ruling from going into effect while the
Natco Pharma cracks 19% as US justices agrees to hear Teva's Copaxone appeal Share More The decision by the Supreme Court comes at a time when Teva is switching its daily version of Copaxone to twice a week version. Natco Pharma plunged as much as 18.
The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment. The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of
Copaxone met the main endpoint in patients with relapsing remitting multiple sclerosis, and that it is the only Phase III study conducted to date with a generic version of Copaxone that was found to have an equivalent efficacy and safety profile to
Having MS today is a lot different than it was a few decades ago. Medications like interferon beta, glatiramer acetate (Copaxone), and others have literally changed the course of this disease -- for the better...Most side effects are minor, but a few
Morgan Stanley and JP Morgan, both of which had made a recommendation of Underweight, have upgraded their recommendations to "Equal weight" and Neutral", respectively. Currently, only Goldman Sachs, also the first institution to publish a warning for
Copaxone dosage to the 40 milligram dosage, which is administered three times a week, instead of daily. Desheh: Splitting Teva will not create value RBC: Teva overoptimistic on large dosage Copaxone "Teva's early progress in shifting daily Copaxone
The guidance does not include patients with highly active MS. The guidance published by the SMC represents an important step in improving the standard of care available to people with MS. Aubagio is the first medicine in Genzyme's pipeline of MS
The patent includes claims to the use of the company's drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases. The patent also includes a claim for the
Neutral" to "Overweight" and raised its target price from $42 to $65, a 31% premium on Friday's closing price of $49.30 on the New York Stock Exchange. The upgrade is part of a general upgrade of US "specialty pharmaceuticals from "Neutral" to "